
Blog · Cancer
Why Does a Prostate Cancer Diagnosis Take So Long?
By Vitae Team ·
Urological referrals are among England's slowest. How the prostate pathway works, where the avoidable delays are, and what to do at 28 days.
New NHS figures published on 12 November show that over the past year, fewer than six in ten people urgently referred and subsequently diagnosed with cancer in England received that diagnosis within 28 days. Urological referrals, which is where suspected prostate cancer goes, are among the slowest. NHS England's own guidance identifies avoidable delays in the prostate pathway, and knowing what that pathway is meant to look like is the most useful thing anyone waiting on one can have.
TL;DR
- The 28-day standard means diagnosed or ruled out within four weeks of an urgent referral. The target is 80%, raised from 75% in March.
- 55.4% of people who turned out to have cancer were told within 28 days over the twelve months to September. For people whose cancer was ruled out, it was 79.1%.
- The headline figure flatters the system, because it combines both groups and most referrals are all-clears.
- Urological referrals are among the slowest. In the April to June quarter, 31.0% of people subsequently diagnosed were told in time, against 54.8% across all cancers.
- Prostate is not published separately. It sits inside the urological figure, so that 31.0% is not a prostate-only number.
- The prostate pathway runs in two stages, an MRI scan and then a biopsy only if the scan warrants one, which needs imaging and urology to coordinate.
- The avoidable delays are documented, including repeat PSA tests before referral that can add two to six weeks.
- If 28 days passes, the hospital team named on your referral letter is who to contact.
What the 28-day standard promises
The Faster Diagnosis Standard says that someone urgently referred for suspected cancer should either have cancer diagnosed or have it ruled out within 28 days. It is deliberately not a treatment target. It covers the period of not knowing, which is the part most people find hardest. The threshold rose from 75% to 80% in March 2026, and the government has committed to hitting 80% by March 2029.
There is a quirk in how the headline number works that is worth understanding before looking at any of the figures. The standard combines two very different groups: people who are told they have cancer and people who are told they do not. Most urgent referrals turn out not to be cancer, so the combined figure is dominated by the all-clears. Overall performance has been running close to the 80% target. The figure for the people who turn out to have cancer has not.
Where the figures sit
Cancer Research UK's analysis, published on 12 November, covers the twelve months from October 2025 to September 2026. Over that year 55.4% of people who were subsequently diagnosed with cancer received that diagnosis within 28 days, against 79.1% of those whose cancer was ruled out. The charity calculated that around 25,400 people would have had their results sooner had the 80% target been met since it rose in March.
The trend is what the charity drew attention to. Across the year, performance for people who turned out to have cancer improved by 0.4 percentage points, while performance for people given the all-clear improved by 1.1. Michelle Mitchell, the charity's chief executive, described waiting to find out as agonising and said people face a double blow, because a slow diagnosis risks a slow start to treatment.
Breakdowns by cancer type are published separately and run behind the headline figures. In Cancer Research UK's August briefing, covering April to June 2026, urological referrals excluding testicular, the group that contains prostate, came in at 31.0% for people subsequently diagnosed, against 54.8% across all cancers. Sarcoma and gynaecological referrals sat in similar territory, so urological is among the slowest rather than uniquely the slowest, and the ranking moves between periods. Prostate is not reported on its own, so none of this is a prostate-specific figure.
How the prostate pathway works
For most suspected cancers, an urgent referral leads to a test that either finds something or does not, and the clock stops. The suspected prostate cancer pathway normally runs in two stages: a multiparametric MRI scan first, and then a targeted biopsy only if the scan suggests one is needed.
That order was introduced as an improvement and NHS England's guidance is clear that it should reduce delay, not add to it. Scanning before biopsying means a substantial number of men avoid a biopsy altogether. National guidance puts the reduction at at least a quarter, and in one research programme 45% of men avoided biopsy. Fewer men undergo an invasive procedure, fewer appointments are needed overall, and the biopsies that do happen target something the scan has identified rather than sampling at random.
What the two-stage structure does require is coordination between imaging, urology and pathology, each with its own capacity and waiting list. Where MRI access is tight or unnecessary appointments are added along the way, the delays accumulate across the handovers. The recommended approach is designed to remove those delays rather than to treat them as the price of a safer diagnosis.
Where the time goes
NHS England's Getting It Right First Time programme published a report on the suspected prostate cancer pathway in April 2024 that identifies the specific points where time is lost. It is national guidance rather than news, and it is unusually direct about what is going wrong. One caveat on its age: it discusses the Prostate Cancer Risk Management Programme as current, and that programme was withdrawn in August 2026, so its PSA testing framework should not be read as today's policy. Its pathway and imaging guidance still stands.
The first delay is repeat PSA testing before referral. The report advises against routinely repeating a raised result simply as a step before referring, because it can add two to six weeks before the hospital clock has even started. The second is an outpatient appointment before the MRI. Many units still bring patients in to be seen before scanning them, which adds a step without adding diagnostic information, when fit patients could go straight to the scan.
The others are capacity and inconsistency. Timely access to MRI before biopsy varies significantly between areas. So do the PSA thresholds that trigger a referral in the first place, which the report links to geographic differences in how late prostate cancer gets caught. Waits for one particular scan type can also hold up treatment when other staging scans are available sooner.
What a good pathway looks like, and what to do if yours is slower
The same report sets out what the best units do. The fastest model is a 14-day one-stop pathway, with MRI and biopsy both done by day seven and the case discussed by a multidisciplinary team by day 14. Where MRI is not needed or not possible, there is a 21-day version, and a 28-day straight-to-test pathway where the scan comes first and biopsy follows. Fit patients should go directly to multiparametric MRI, and biopsy where needed should be a local anaesthetic transperineal procedure done as an outpatient.
Knowing that shape is worth something if you are in it. It tells you that an MRI appointment is usually the next milestone rather than a consultation, that some areas complete the whole process inside a fortnight, and that a long gap before the scan is where most pathways slip. None of it is a guarantee about your own hospital, which may run a different version of the pathway for reasons that make sense locally. What it gives you is a sense of whether what is happening to you resembles what is meant to happen.
If 28 days passes without a diagnosis or an all-clear, the people to contact are the hospital team handling your referral, using the details on the letter you were sent. If you cannot find them, your GP practice can tell you where the referral went. A clinical nurse specialist is worth asking if one has been assigned to you, though at the pre-diagnosis stage many people do not yet have one. It is also worth knowing that passing the 28 days is a measure of how the service is performing, not a signal about your own result.
What This Actually Means
The headline that half of people wait too long is accurate but blunt, and the detail underneath it matters more. The system is reasonably quick at telling people they do not have cancer and markedly slower at telling people they do, and the gap between those two has been widening rather than closing. That pattern is worse again in urological referrals.
The two-stage prostate pathway is not the villain here, and it would be easy to present it as one. It was introduced to spare men invasive procedures and it does that. The problem is in the joins: imaging capacity that depends on where you live, appointments inserted that add nothing, and blood tests repeated before a referral that did not need repeating. NHS England has identified all three in its own guidance, which means they are recognised rather than disputed.
For a reader, most of this is outside your control. What is not is knowing the shape of the thing you are waiting on, and knowing who to ring when the four weeks are up. The waiting is the hardest part of this process and it is also the part most people go through with the least information about what is supposed to happen next.
Frequently Asked Questions
What does the 28-day standard cover?
The time from an urgent referral to being told either that you have cancer or that you do not. It is not a target for starting treatment. That is a separate 62-day standard, which has not been met nationally since December 2015.
Is the 31.0% figure specifically about prostate cancer?
No. It covers urological referrals excluding testicular cancer, which includes prostate along with kidney and bladder, and it is a quarterly figure rather than the latest annual one. Prostate is not published as its own category.
Why do I need an MRI before a biopsy?
Because it means many men avoid a biopsy altogether, and it lets the biopsy target a specific area rather than sampling at random. National guidance puts the reduction in biopsies at at least a quarter.
Should I ask for a second PSA test?
Not routinely. NHS England's pathway guidance advises against repeating a raised PSA simply as a step before referral, because it can add weeks. A clinician may still want another test where infection, a recent procedure or something else could have affected the result. Ask your GP why a repeat is needed and whether it changes the referral decision.
My 28 days are up and I have heard nothing. What should I do?
Contact the hospital team named on your referral letter. Your GP practice can tell you where the referral was sent if you cannot find the details, and a clinical nurse specialist can help where one has been assigned. Passing 28 days reflects service performance, not your result.
The Bottom Line
Over the past year, 55.4% of people urgently referred and later diagnosed with cancer in England were told within 28 days, against a target of 80%, while 79.1% of those given the all-clear were told in time. Urological referrals, which contain prostate without being published separately, sit among the slowest groups at around three in ten in the most recent quarterly breakdown.
The two-stage prostate pathway, MRI first and biopsy only if needed, exists for good reasons and spares a lot of men an invasive procedure. Where time is lost is in the joins and in the steps that should not be there, and NHS England's own guidance names them. If you are waiting, the two things most worth having are an idea of what the pathway is supposed to look like and the phone number of the team holding yours.
This article is for general information and is not medical advice. If you have symptoms or concerns about prostate cancer, or questions about your own referral, speak to your GP or the clinical team handling your care.
Sources
- Cancer Research UK. 25,400 people should have received a cancer diagnosis faster in England in the last six months, 12 November 2026. (Figures cover October 2025 to September 2026.) https://news.cancerresearchuk.org/2026/11/12/25400-people-should-have-received-a-cancer-diagnosis-faster-in-england-in-the-last-six-months/
- Cancer Research UK. Waiting times stall on diagnosis for people with cancer, 12 November 2026. https://news.cancerresearchuk.org/2026/11/12/waiting-times-stall-on-diagnosis-for-people-with-cancer/
- Cancer Research UK. Cancer waiting times across the pathway: key statistics, August 2026. (Faster Diagnosis Standard by tumour group, April to June 2026.) https://www.cancerresearchuk.org/health-professional/cancer-statistics/cancer-waiting-times
- Cancer Research UK. Variation in performance on the Faster Diagnosis Pathway, September 2025. https://www.cancerresearchuk.org/health-professional/our-reports-and-publications/variation-in-performance-on-the-faster-diagnosis-pathway
- Getting It Right First Time, NHS England. Urology: towards better diagnosis and management of suspected prostate cancer, April 2024. https://gettingitrightfirsttime.co.uk/wp-content/uploads/2024/04/GIRFT-Urology-Towards-Better-Diagnosis-Management-of-Suspected-Prostate-Cancer-FINAL-V1-April-2024-1.pdf